VITA 34 AG (0NLV.L)

4.4000 -0.5800 (-11.65%) At close: 05:27PM BST

VITA 34 AG

Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de

Sector(s): 
Industry: 
Full-time employees: 815

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jakub Julian Baran	Chairman of the Management Board & CEO	N/A	N/A	N/A
Mr. Tomasz Franciszek Baran	Vice President of the Management Board & Chief Commercial Officer	N/A	N/A	N/A
Santiago Luengo	Managing Director of Secuvita	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces viral vectors and CAR-T cells. The company manufactures advanced therapy medicinal products for third parties. In addition, it offers a range of products for long-term storage of biological material obtained at birth, as well as placental blood or umbilical cord tissue or placenta tissue. Further, the company provides sperm banking services for freezing sperm; adipose tissue banking services as a source of mesenchymal stem cells and stromal vascular fraction; medical consultations and non-diagnostic ultrasound examination services; and other contract manufacturing services for classical transplantations or cell and gene therapies. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

Corporate governance

VITA 34 AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.